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Towards simplified oral lipid-based drug delivery using mono-/di-
glycerides as single component excipients 
Objective 
This study aimed to systematically explore compositional effects for a series of 
lipid systems, on the in vitro drug solubilization and in vivo bioavailability of 
three poorly water-soluble drugs with different physico-chemical properties.  
Significance 
While many lipid-based drug products have successfully reached the market, 
there is still a level of uncertainty on the design guidelines for such drug products 
with limited understanding on the influence of composition on in vitro and in 
vivo performance. 
Methods & Results  
Lipid-based drug delivery systems were prepared using either single excipient 
systems based on partially digested triglycerides (i.e. mono- and/or di-glycerides) 
or increasingly complex systems by incorporating surfactants and/or 
triglycerides. These lipid systems were evaluated for both in vitro and in vivo 
behaviour. Results indicated that simple single component long chain lipid 
systems are more beneficial for the absorption of the weak acid celecoxib and the 
weak base cinnarizine compared to equivalent single component medium chain 
lipid systems. Similarly, a two-component system produced by incorporating 
small amount of hydrophilic surfactant yields similar overall pharmacokinetic 
effects.  The lipid drug delivery systems based on medium chain lipid excipients 
improved the in vivo exposure of the neutral drug JNJ-2A. The higher in vivo 
bioavailability of long chain lipid systems compared to medium chain lipid 
systems was in agreement with in vitro dilution and dispersion studies for 
celecoxib and cinnarizine.  
Conclusions 
The present study demonstrated the benefits of using mono-/di-glycerides as 
single component excipients in LBDDS to streamline formulation screening and 
improve oral bioavailability for the three tested poorly water-soluble drugs.  
 
Keywords; Lipid-based drug delivery systems, Long versus medium chain lipid 












Lipid-based drug delivery systems (LBDDS) have been widely explored to overcome 
pharmaceutical developability challenges for poorly water-soluble drugs (PWSD) [1-3]. 
Typical consequences of low solubility in the aqueous gastrointestinal environment 
upon oral administration are poor absorption and food dependent bioavailability, thus 
increased variability in therapeutic responses [4,5]. Formulation of a PWSD in a 
LBDDS confers numerous biopharmaceutical advantages. These include increased drug 
solubility, but co-administration of lipid excipients also stimulates a number of 
physiological events  promoted by food, resulting in increases in endogenous biliary 
lipid concentrations in the intestine (i.e. bile salts, phospholipids and cholesterol), 
leading to greater drug solubilization in the intestinal mixed micellar milieu [6,7]. The 
ability to (a) enhance drug solubility on dispersion in intestinal fluid and (b) maintain 
drug solubilisation within the gastrointestinal tract (GIT) are considered key bio-
enabling characteristics for LBDDS [2,3]. 
Despite numerous commercially available lipid-based drug products and 
significant pre-clinical  research in the field [8], there is still a reticence in many 
industry sectors towards advancing LBDDS as a lead formulation for use in clinical 
trials and/or commercially licensed drug products. Possible reasons for this may include 
a lack of clear guidance on formulation design of LBDDS, limited comprehensive 
understanding regarding compositional influence on in vivo behaviour and a lack of 
predictive in vitro 
models for assessment of drug absorption from lipid systems [4]. Typically, the 
rationale underpinning choice of LBDDS is highly influenced by the organisation's 
expertise, as well as availability of scientific knowledge and manufacturing platforms 










maps and decision trees are welcome, many questions on composition influence remain 
unclear [1,5]. The main objective of this study was to identify approaches that 
streamline formulation screening and allow the potential benefits of lipid excipients to 
be identified as early as possible in an industrial drug development setting.  
While there has been considerable focus in the scientific literature on developing 
compositionally complex LBDDS, with multiple excipients including oils, surfactants, 
co-surfactants, and co-solvents (commonly referred to as LFCS type III and IV 
according to Lipid Formulation Classification System (LFCS) [9]), it is interesting to 
contrast this with the findings of two separate reviews of commercially available 
LBDDS which indicated the predominance of single component marketed LBDDS 
[6,8]. While the scientific rationale supporting the trend towards Type III/IV systems 
relates to advantages in terms of improving drug solubility and in vitro dispersibility 
with ‘digestion-independent’ systems, clearly, from an industrial development 
perspective, there is a preference for simple LBDDS compositions in terms of 
streamlining excipient screening and lowering the regulatory burden. In this study, the 
biopharmaceutical benefits of partially digested triglycerides (i.e. mono- and/or di-
glycerides) were investigated as single excipient LBDDS or mixed in more complex 
LBDDS. This was, to the best of our knowledge, the first study to investigate such 
simple systems based on partially digested triglycerides from both in vitro and in vivo 
perspectives.  
Lipid excipients containing partially digested glycerides are generally lipolytic 
products of triglycerides (i.e. mono- and di-glycerides) which have been reported to 
display higher solubilization capacities and improved dispersibility properties relative to 
triglycerides [10]. Due to their amphiphilic surfactant-like properties, monoglycerides 










endogenously produced upon digestion of triglycerides, and together with fatty acids, 
phospholipids, bile salts and cholesterol constitute the pre-absorptive colloidal 
solubilizing environment in the GIT. These highly dispersed colloids are efficient in the 
transport of lipophilic compounds across the unstirred water layer (UWL) to the 
absorptive surface of the intestine [3]. The use of blends of partially digested glycerides 
and further addition of hydrophilic surfactants is increasingly popular among LBDDS 
(classified as Type IIIA according to LFCS) as they exhibit less dependence on 
digestion in comparison to type I pure oil systems and upon dispersion and digestion 
these result in moderate degrees of drug supersaturation, with a lower precipitation risk. 
The in vitro and in vivo behaviour of LBDDS vary considerably with the chain 
length of the lipid components. Previous studies have reported higher bioavailability 
when administered in LBDDS containing long chain (LC) instead of medium chain 
(MC) triglycerides for drugs including cyclosporine, probucol, vitamin D3, dicoumarol, 
danazol  [11,12]. In contrast, the in vivo performance of vitamin E, SL-512, 
progesterone, penclomedine, acetylsulfisoxazole and griseofulvin was improved after 
administration in MC lipids when compared to LC lipids [11,12]. There are also reports 
where lipid chain length had no influence on performance of drugs such as 
dexamethasone, seocacitol, an investigational new drug candidate (CDA) and anethole 
trithione [11,13,14].  
To date, numerous studies have attempted to develop in vitro screening 
approaches to predict in vivo relations (IVIVR) of LBDDS, ranging from simple 
dilution/dispersion tests to more complex lipolysis models and, more recently digestion-
permeation models aimed to simulate in vivo scenarios [15,16]. While many of the more 
complex in vitro tools provide useful mechanistic insights to the IVIVR for LBDDS, 










high throughput screening (HTS) and provide developability guidance (or indeed risks 
thereof) in shorter timeframes (i.e. hours/days). Therefore, the aims of this study were: 
(1) to systematically investigate the influence of lipid components in LBDDS on in vivo 
behaviour of three PWSD with different physico-chemical properties; (2) to assess the 
differences in drug solubilization capacity, dispersibility under biorelevant conditions, 
and propensity for precipitation upon dilution of LBDDS with different composition 
complexities and (3) to explore the utility of IVIVR in early pharmaceutical 
development of bio-enabling formulations such as LBDDS. 
2. Materials and Methods 
2.1.Materials 
Three poorly water-soluble drugs were used in this study. Celecoxib (weak acid, 381.4 
g/mol, logP = 4.3) was purchased from Astatech Inc. (Bristol, PA, USA), cinnarizine 
(weak base, 368.5 g/mol, logP = 5.7) and JNJ-2A (neutral, 498.9 g/mol, logP = 5.4) 
were obtained from Janssen Pharmaceutica (Beerse, Belgium). Analysis of plasma 
samples containing celecoxib and cinnarizine was done using internal standards: 
ibuprofen (for celecoxib samples) and flunarizine (for cinnarizine samples) according to 
[17] and [18], respectively. Both ibuprofen and flunarizine were obtained from Janssen 
Pharmaceutica (Beerse, Belgium). Sesame oil (long chain triglycerides, LCT) was 
purchased from Croda (Chocques, France), Capmul MCM C8 (medium chain mixed 
glycerides, MCM) was kindly donated by Abitec (Columbus, OH, USA). Maisine CC 
(long chain mono-/di-glycerides, LCM), Labrafac Lipophile WL1349 (medium chain 
triglycerides, MCT) and Labrasol ALF (hydrophilic surfactant, S) were kind gifts from 
Gattefossé (Lyon, France). SIF powder was obtained from biorelevant.com (London, 










purchased from WVR (Belgium). 
2.2.Methods 
2.2.1. Design of prototype lipid systems 
The composition of the excipients used for the eight LBDDS designed in this study is 
shown in Supporting information Table S 1. These LBDDS were: 1) one-component 
systems containing LC or MC partially digested triglycerides (blends of mono- and di-
glycerides; LCM, MCM), 2) two-component systems containing also hydrophilic 
surfactant  (LCM+S, MCM+S), 3) three-component systems with the same fatty acid 
chain length (LCM+LCT+S, MCM+MCT+S), and 4) three-component systems with 
different fatty acid chain length (LCM+MCT+S, MCM+LCT+S). Excipients for each 
LBDDS were mixed gently for 10 s at ambient temperature until a homogenous solution 
was obtained.  
2.2.2. Drug solubility in blank lipid systems 
Solubility of drugs (i.e. celecoxib, cinnarizine and JNJ-2A) in the prototype lipid 
systems was determined by the shake-flask method at 37°C. Additionally, solubility in 
LC and MC pure triglycerides (i.e. sesame oil – LCT and Labrafac Lipophile – MCT) 
was determined, to evaluate differences between different classes of lipid excipients. In 
short, an excess amount of drug was added to 1 mL of each lipid excipient or mixture in 
vials containing a magnetic stirrer. Formed suspensions were continuously stirred at 
37°C for 24 h. The same experimental design was first pre-tested for the three drugs at 
24, 48 and 72 h to determine if equilibrium solubility (Seq) was reached within 24 h. 
Aliquots of the mixtures were centrifuged at 17500 rpm for 30 min using an Eppendorf 










performed in triplicate. 
2.2.3. Preparation of drug-loaded lipid systems 
Based on the solubility values at 37°C, the amount of drug to be weighted was 
calculated to correspond to an 85% saturation degree in each of the tested lipid systems. 
The required mass of drug (Table 1) was weighted into clean screw-top glass vials and 
drug-free lipid systems were added up to the target drug loading. Vials were sealed, 
mixed and incubated at 37°C for 24 h prior to testing. 
2.2.4. In vitro evaluation: Drug solubility in biorelevant media 
Drug solubility in six biorelevant media was determined in order to evaluate the 
influence of LC and MC lipid excipients on in vitro solubilization behaviour of the three 
drugs used in this study. The six media represent either: (1) level II biorelevant media 
(i.e. fasted state simulated intestinal fluid - FaSSIF and fed state simulated intestinal 
fluid – FeSSIF [19,20], (2) FaSSIF with dispersed LCM and MCM and (3) two post-
digestive assembled media containing FaSSIF and digestion products of LCM (i.e. 
Maisine CC = mono- and di-glycerides of C18:2, C18:1, C18:0, C16) and MCM (Capmul 
MCM = mono- and di-glycerides of mainly C8).  
FaSSIF and FeSSIF were prepared according to general instructions suggested 
by biorelevant.com using SIF powder and phosphate buffer, whereby FaSSIF was only 
used after 2 h of room temperature storage and FeSSIF was used immediately after 
preparation.  Dispersed media were prepared according to Gautschi and co-workers 
[21], with slight modifications, by dispersing the undigested lipid excipient (LCM, 
MCM) in FaSSIF and continuously stirring at 300 rpm in a climate chamber at 37°C in 
a dilution of 1:40 lipid to FaSSIF for 2 h. For the post-digestive biorelevant media 










employed similar to Gautschi et al. [21]. In the present study, it was assumed that the 
monoglycerides in the lipid excipients were not further digested and that diglycerides 
(DG) and the traces of triglycerides (TG) digest to the respective monoglycerides and 
free fatty acids in molar ratio of 1:1 for DG and 1:2 for TG. For simplification purposes, 
only one fatty acid (i.e. linoleic acid, C18:2), which was in the highest concentration 
according to the certificate of analysis of Maisine CC, was considered in the 
composition of LCM. Therefore, the digestion products of Maisine were assumed to be 
monolinolein and linoleic acid (1 g Maisine presumably digests to 0.71 g monolinolein 
and 0.29 g linoleic acid). Similarly, for Capmul MCM, only caprylic acid (C8) was 
considered the predominant fatty acid, thus the proposed digestion products used were 
monocaprylin and caprylic acid (1 g Capmul MCM presumably digests to 0.83 g 
monocaprylin and 0.17 g caprylic acid). Assembled media containing digestion 
products of LCM and MCM were stirred continuously at 37°C for 2 h. 
Equilibrium solubility of celecoxib, cinnarizine and JNJ-2A was assessed at 
37°C in the six biorelevant media by the shake-flask method described above. Samples 
were collected at 2, 4, 6 and 24 hours, centrifuged using an Eppendorf centrifuge and 
clear supernatant was diluted with diluent containing 50% N-Methyl-2-pyrrolidone 
(NMP) in Milli-Q water (v/v). Apparent drug concentration was assessed using the 
reverse-phase methods described in section 2.2.6 and results are shown as mean + SD. 
2.2.5. In vitro evaluation: Precipitation and drug solubilization upon dilution 
and dispersion 
The dilution, dispersion and precipitation characteristics of the different lipid systems 
containing the three drugs at 85% saturation degree were evaluated in FaSSIF at a 1:250 
dilution ratio in triplicate. The diluted samples were stirred with a magnetic stirrer to 










intervals (0, 0.25, 1, 2, 4, 24 h), the samples were investigated both macroscopically for 
the presence of precipitate and analytically for determination of drug concentration in 
the aqueous dispersed phase using the methods described in section 2.2.6. To determine 
the apparent drug concentration in the aqueous phase of the dispersed lipid systems, 
samples were withdrawn using a 1 mL syringe and centrifuged for 10 min at 17500 rpm 
and 37 °C in a benchtop Eppendorf centrifuge. Clear supernatant was diluted with 
diluent containing 50% NMP in Milli-Q water and measured with an Acquity Ultra 
Performance Liquid Chromatography (UPLC™) H-class system (Waters, Milford, 
USA) as shown in section 2.2.6. Drug precipitate formed during dispersion of lipid 
systems in FaSSIF was transferred onto zero background holders and analysed with X-
ray powder diffraction (XRPD) from 3° to 50º 2θ. The analysis was carried out on a 
PANalytical (Philips, Amsterdam, The Netherlands) X’PertPRO MPD diffractometer, 
equipped with a Cu LFF X-ray tube. Diffractograms were compared to the ones 
corresponding to the crystalline drug material which was used for drug-loading of lipid 
systems. 
2.2.6. Drug quantification in in vitro samples  
The drug concentration in the supernatants obtained after centrifugation was determined 
using an Acquity (UPLC™) H-class system consisting of a binary solvent manager, a 
sample manager and a photodiode array (PDA) detector. The output signal was 
monitored and processed using the Empower
®
 software version 3.0. A reversed-phase 
(RP) Waters Acquity BEH C18, 50 mm × 2.1 mm column packed with 1.7 μm particles 
(Waters, Milford, USA) was used for the chromatographic analysis with a mobile phase 
containing a gradient mixture of solvents A (0.1% trifluoracetic acid in water) and B 
(100% acetonitrile – ACN) in the following A/B proportions: 60/40 for celecoxib and 










for celecoxib and cinnarizine and 0.75 mL/min for JNJ-2A and the injection volume 
was 2 μL. The column temperature was maintained at 55°C and the wavelength was 
monitored at 251 nm (celecoxib), 253 nm (cinnarizine) and 280 nm (JNJ-2A). The 
calibration curves for the three drugs were confirmed linear between 2.5 – 100 µg/mL 
and samples were diluted accordingly. The solubility experiment was performed in 
triplicate. 
2.2.7. In vivo evaluation: Rat pharmacokinetic study 
The protocol used for the in vivo pharmacokinetic studies was approved by the 
institutional animal ethics committee in accordance with the Belgian law regulating 
animal use in experimental procedures. The study was in compliance with EC Directive 
2010/63/EU and the NIH guidelines on animal welfare. Male Sprague-Dawley rats 
weighting between 250-300 g, received 0.5 mL/kg lipid solution of celecoxib (n=4), 
cinnarizine (n=4) and JNJ-2A (n=6) by oral gavage. Lipid systems were stirred 
continuously the night before dosing and were clear upon oral administration. Blood 
was collected after oral administration at defined timepoints: 0.5, 1, 2, 4, 6, 8, 24 h for 
cinnarizine and celecoxib and at 0.5, 1, 2, 4, 8, 10, 24 for JNJ-2A. A small volume (30 
µL) of blood was collected into EDTA-plasma tubes and 10 µL of the plasma were 
harvested after centrifugation in end-to-end pipettes and analysed with LC/MS-MS for 
six of the celecoxib administrations and the JNJ-2A LBDDS. For two celecoxib (CCX) 
LBDDS (i.e. LCM and MCM) and for the whole set of cinnarizine (CIN) lipid systems, 
100 µL plasma was harvested and bioanalysis was performed on a Waters UPLC™ 
system with UV-detection. 
2.2.8. Quantitative analysis of plasma samples 










and of JNJ-2A after oral dosing of all eight lipid systems was performed on a  Sciex 
API-4000 triple quadrupole mass spectrometer (Sciex, Ontario, Canada) equipped with 
an Acquity UPLC™ (Waters, Milford, MA, USA).. Separation was done on an 
ACQUITY UPLC™ BEH C18 1.7 µm particles, 50  2.1 mm column, using a gradient 
of 0.1% formic acid and acetonitrile (for celecoxib) and 0.1% formic acid and 0.01M 
Ammonium carbonate (for JNJ-2A).  The flow rate was kept at 0.80 mL/min and 
method linearity was between 1 – 10000 ng/mL (celecoxib) and 4 – 20000 ng/mL (JNJ-
2A). 
Ibuprofen (IBU) was added as internal standard for the quantification of 
celecoxib in plasma samples after oral dosing of single component lipid solutions (i.e. 
LCM and MCM) and flunarizine (FLU) as internal standard for cinnarizine 
measurements after dosing of all eight lipid systems [17,18]. Ibuprofen and flunarizine 
were solubilized in acetonitrile to obtain internal standard solutions, 140 µL of these 
solutions were added to 20 µL plasma sample containing either celecoxib or 
cinnarizine. Plasma protein precipitation was successful after centrifugation for 30 min 
at 17500 rpm using an Eppendorf centrifuge 5430R (Eppendorf, Hamburg, Germany). 
The extraction recovery of celecoxib was ≥ 93.3% and of cinnarizine ≥ 96.6%. All other 
analytical parameters were identical to the reverse-phase methods described above for 
quantification of in vitro samples. The concentrations of celecoxib and cinnarizine were 
determined by standard calibration curve analysis using linear fitting of a plot of 
CCX/IBU peak area ratios versus celecoxib concentrations and CIN/FLU peak area 
ratios versus cinnarizine concentrations, respectively. The standard calibration curves 











2.2.9. Pharmacokinetic and statistical analysis 
The primary pharmacokinetic parameters: area under the plasma concentration-time 
curve (AUC), maximum plasma concentration (Cmax) and time to reach Cmax (tmax) were 
obtained by non-compartmental analysis of the plasma data, using the linear trapezoidal 
method in Microsoft Excel (Office 365) with PKSolver add-in. Multiple sample 
comparison was tested by an analysis of variance (ANOVA) on ranks of dose-
normalized data for the pharmacokinetic parameters Cmax, tmax and AUC0–24h using 
SigmaPlot 12.5 from Systat Software, Inc. (Chicago, IL, USA). A statistical p-
value<0.05 was considered significant. For statistical contrast analysis a Tukey post-hoc 
test was used. Results are expressed as mean ± SD for Cmax and AUC0–24h and median 
[min, max] for tmax. Pearson correlation coefficients for in vitro and in vivo relations 
were computed using GraphPad Prism version 8.4.3 (San Diego, CA, USA) and are 




3.1.Comparing drug solubility in partial glycerides versus triglycerides  
Equilibrium drug solubility in four classes of lipid excipients was determined at 37 °C. 
Lipid excipients were chosen to represent long chain triglycerides (LCT –  sesame oil), 
long chain blends of mono- and di-glycerides (LCM – Maisine CC), medium chain 
triglycerides (MCT – Labrafac Lipophile WL 1349) and medium chain mono- and di-
glycerides (MCM – Capmul C8 MCM). Results are shown in Figure 1.  
A clear difference in solvent capacity was observed between excipients 
composed of blends of mono-/di-glycerides and pure triglycerides for celecoxib and 
JNJ-2A for both long and medium chain lipid classes. For cinnarizine, the highest 










slightly higher solvent capacity relative to MCT. Low drug solubility in triglyceride 
vehicles, leading to limited dose loading, is often a limitation for choosing a simple TG-
based drug delivery system, particularly for low potency/high dose drug candidates 
[8,9]. Drug solubility was higher in blends of mono-/di-glycerides, in line with previous 
literature on other lipophilic drugs [22-24]. The enhanced solvent capacity of partially 
digested triglycerides may reduce the need for inclusion of hydrophilic surfactants 
and/or co-solvents.  
3.2.Comparing drug solubility in FaSSIF/FeSSIF media versus biorelevant 
dispersions of partial glycerides 
Drug solubility in six types of biorelevant media was determined to assess simulated in 
vivo drug solubility under fasting conditions (FaSSIF); fed state conditions (FeSSIF); 
conditions that simulate in vivo solubilisation on dispersion in fasted state intestinal 
fluids (FaSSIF + LCM) and FaSSIF + MCM (1:40) ); conditions that simulate post-
digestive conditions (FaSSIF and lipolytic end products of LCM and MCM digestion). 
Solubility values obtained after 6 hours of continuous stirring in the tested media are 
presented in Figure 2. 
Solubility in FaSSIF was relatively low for the three tested drugs, ranging 
between 14 and 80 µg/mL, while an increase of approximately 3-fold (celecoxib), 15-
fold (cinnarizine) and 7-fold (JNJ-2A) was observed in the fed state simulating media 
(FeSSIF) indicating enhanced drug solubility in the post prandial conditions for these 
three drugs and a potential food effect (Figure 2). For the biorelevant dispersions of 
partial glycerides, the solubility of each drug in the LCM dispersions was similar to 
FaSSIF solubility. This indicated that the addition of the LCM excipient had limited 
effect on drug solubilisation on initial dispersion relative to the fasted state. In contrast, 










closely matched the solubility in FeSSIF indicating that the enhanced solubilisation in 
the post prandial state could potentially be addressed by employing an LCM excipient 
in the formulation of LBDDS containing celecoxib, cinnarizine or JNJ-2A. 
In case of MCM based biorelevant dispersion, all three drugs displayed lower 
drug solubility relative to FaSSIF. This may be a reflection of observed drugs tendency 
for forming complexes with the medium chain lipid excipient leading to reduce 
solubilisation of the drug in the assembled media. Under simulated post-digestive 
conditions, the solubility of JNJ-2A was low and unchanged compared to dispersed 
MCM in FaSSIF. For cinnarizine the solubility improved under simulated digestive 
conditions, but was in general in the same range as the solubility in FaSSIF. 
Collectively these results suggested there were no solubility advantages including MCM 
lipid excipient for either JNJ-2A nor cinnarizine. In contrast, celecoxib displayed a 17-
fold higher solubility observed in the MCM simulated post-digestive conditions when 
compared to FaSSIF solubility. In summary, this relatively rapid solubility screening 
test, designed to simulate biorelevant dispersion and digestion conditions, may be a 
useful guide on the choice of lipid chain length in LBDDS. In the case of cinnarizine 
and JNJ-2A LCM-containing LBDDS were predicted to display higher in vivo 
solubility, whereas for celecoxib MCM-containing LBDDS were estimated to display 
higher in vivo solubility in the post-digestive environment.  
3.3.In vitro dilution and dispersion in FaSSIF 
The dispersion characteristics of the different LBDDS loaded with either celecoxib, 
cinnarizine or JNJ-2A were evaluated following dispersion in FaSSIF (1:250 v/v).  All 
eight lipid systems formed turbid dispersions with no macroscopically visible drug 
precipitate. The single component (LCM and MCM) and two component (LCM+S and 










small oil droplets at the surface of the dispersion. The three component systems 
displayed improved dispersibility (i.e. no visible oil droplets). At different timepoints, 
drug concentration was determined and is presented in Figure 3 as percentage of drug 
solubilized in the aqueous environment relative to initial (theoretical) drug 
concentration upon LBDDS dispersion. 
For all three drugs, a trend towards higher percentage of drug solubilized in the 
aqueous environment during the 24 hours of testing was evident for the one component 
LC LBDDS. Percentages relative to theoretical drug solubilized in the whole dispersion 
medium of 20-40% for celecoxib, 10-25% for cinnarizine and 20–50% for JNJ-2A were 
determined. For the two-component LCM+S system high percentages were also 
calculated (10-30% for celecoxib, 15-20% for cinnarizine and 15-25% for JNJ-2A). One 
or two component MC LBDDS displayed the lowest percentage of drug solubilized in 
the aqueous phase (celecoxib – 2-20% [MCM], 1-2% [MCM+S]; cinnarizine – 1-2% 
[MCM], 4-9% [MCM+S] and JNJ-2A - 0.7-6% [MCM], 4-10% [MCM+S]). Despite 
displaying a better dispersibility in biorelevant media, for the three component systems 
percentages of drug solubilized were similar to LCM and LCM+S dispersions (15-27% 
for celecoxib and 10-15% for cinnarizine). In contrast, addition of triglycerides to MC 
systems improved both the dispersibility and the drug solubilization compared to the 
one and two component MC systems (13-20% for celecoxib, 10-18% for cinnarizine 
and 2-10% for JNJ-2A). 
Celecoxib precipitation between 0-2 h was observed in all LBDDS, except for 
LCM which showed precipitate at 4 h (Supporting information, Table S 2). Cinnarizine 
only showed precipitate during the screening in MC LBDDS. Both celecoxib and 
cinnarizine precipitated as crystalline material as illustrated by XRPD diffractograms, 










(Supporting information, Figure S 1 and Figure S 2). Notably, there was no 
precipitation observed for JNJ-2A in all dispersions. However, phase separation or 
‘oiling out’ occurred in all JNJ-2A dispersions following centrifugation of the sample, 
with distinct oil droplets forming either as an upper layer in the vial on top of the 
aqueous phase for LCM-containing systems or as a lower oil layer for MCM-containing 
systems. 
3.4.Assessing compositional effect in vivo 
The plasma concentration versus time profiles following oral administration to rats of 
three drugs in eight LBDDS is presented in Figure 4. In all cases the drug saturation 
degree in the drug delivery system was fixed at 85% and the dosing volume of 0.5 
mL/kg was maintained constant across all tested lipid systems. As a result, the dose was 
different between groups depending on the drug solubility in each system (Table 2) and 
drug concentrations in plasma were hence dose-normalised to facilitate direct 
comparison of formulation effects. In the case of celecoxib and cinnarizine, reference to 
previous published studies in rats indicate dose proportionality at doses between 12.5-
100 mg/kg (celecoxib) and 2-30 mg/kg (cinnarizine) [17,25]. In case of JNJ-2A, no 
previously published reports were available to confirm dose proportionality, however 
in-house internal pharmacokinetic studies demonstrated that dose proportionality was 
observed at <100 mg/kg whereas at doses between 100 – 200 mg/kg dose 
proportionality was evident for AUC0-24h but not for Cmax (Janssen internal data). A 
comparison of dose-normalised AUC0-24h as a function of LBDDS composition is 
presented in Figure 5 and the corresponding pharmacokinetic parameters are illustrated 
in Table 3.  
For celecoxib, Cmax after dosing of LBDDS containing at least one LC lipid 










component LCM system being statistically significant relative to all LBDDS except 
LCM+S. Similarly, celecoxib exposure, as expressed by AUC0-24h, was the highest after 
dosing of LCM and LCM+S. In case of cinnarizine, Cmax after dosing of LCM+S was 
statistically higher compared to MCM, while the AUC0-24h after administration of LCM 
was statistically higher relative to MCM+S. The overall higher bioavailability of LC 
LBDDS was seen for both celecoxib and cinnarizine compared to the corresponding 
MC systems. For JNJ-2A, no statistically significant difference was observed for Cmax in 
the tested LBDDS; however, a statistically significant difference was observed for the 
one component MC lipid system relative to its LC correspondent for AUC0-24h. No 
statistically significant differences were observed for tmax amongst the tested LBDDS 
for the three model drugs, with a relatively fast absorption (≤ 4h) of celecoxib and 
cinnarizine and a longer absorption of JNJ-2A (3-9.5h). No statistically significant 
differences were found for triglyceride-containing LBDDS.  
3.5.In vitro – in vivo relation 
In an attempt to identify possible relations between in vitro observations and in vivo 
pharmacokinetics, plots of AUC0-24h of drug concentration determined in the aqueous 
phases after dispersion in FaSSIF (Table S 3) and of plasma concentration versus time 
after oral administration (Table 3) were constructed. Additionally, the Pearson 
correlation coefficients were calculated and are presented as R
2
. While overall the in 
vitro – in vivo relations were poor (R
2
 was between 0.006 and 0.046), the higher 
solubilization in biorelevant media after LCM+S dispersion correlated with high in vivo 
performance of the lipid system (full squares, Figure 6) for all three drugs. Individually, 
by visual observation (Figure 6), for celecoxib a good correlation between in vitro and 
in vivo results was seen for LCM, in case of cinnarizine for LCM, LCM+LCT+S and 










addition, it seems that poor in vivo performance of MCM and MCM+S (empty circles 
and squares) containing celecoxib and cinnarizine (Figure 6, graph A and B 
respectively) could be linked to the low drug solubilization in FaSSIF upon dispersion. 
4. Discussion 
Pharmaceutical academic research has particular relevance when it focuses on the needs 
of the pharmaceutical industry, for example in advancing compositional understanding 
on LBDDS, thus increasing industrial uptake of this bio-enabling technology. A 















) was identified, 
while considerable academic research is invested to study complex LBBDS with 
compositions in excess of three excipients, which can be highly resource intensive in an 
accelerated screening pharmaceutical development setting. A key focus of this study is 
therefore to identify the potential merits of one or two component LBDDS, which are 
well suited to HTS and accelerated pharmaceutical development paradigm, as well as to 
compare with more compositionally complex LBDDS. 
This study demonstrated the benefits of simple, one and two component 
LBDDS, over more complex systems for an improved drug absorption. In particular, the 
use of blends of mono-/di-glycerides as single component LBDDS offered a balance in 
terms of streamlining drug-excipient screenings/formulation characterisation and 
showed enhanced in vivo exposure for celecoxib, cinnarizine and JNJ-2A in rats. Such 
simple blends therefore bear much potential either as components or final formulation 





, dutasteride – Avodart
®
) are formulated using only blends of MC 
mono-/di-glycerides [8]. In contrast, the analysis of three reviews on bio-enabling 










blends of mono-/di-glycerides, which the current work found to be suitable for 
enhancing the bio-performance of both celecoxib and cinnarizine. Several oral 
pharmacokinetic preclinical studies have suggested that inclusion of celecoxib in 
compositionally complex self-(micro)-emulsifying drug delivery systems (S(M)EDDS) 
improve the drug’s bioavailability compared to aqueous suspension [27] and 
conventional capsule [28]. Celecoxib was also used for successful formulation design of 
a bio-enabling silica-lipid hybrid (SLH) microcapsule system with several physico-
chemical and biopharmaceutical benefits over unformulated drug, lipid emulsion, dry 
emulsion and the commercial product Celebrex
®
 [29,30]. Similarly, for cinnarizine it 
has been shown that administration as LBDDS in the form of lipid solutions [25], 
SEDDS, or self-nano-emulsifying drug delivery systems (SNEDDS) [18,31-36], sub-
microemulsions [37], silica-stabilized lipid cubosomes, silica-solid lipid hybrid, and 
polymer − lipid hybrid particles [38] exhibited bioavailability advantages relative to 
conventional formulations.   
There is clear evidence in the literature that highly lipophilic drugs administered 
in a LBDDS have improved absorption compared to conventional formulations [39]. 
However, while numerous studies focus their hypotheses on comparing LBDDS to 
alternative bio-enabling formulations e.g. amorphous solid dispersions, relatively few 
studies compared between LBDDS to elucidate the potential compositional effects on in 
vivo performance [11]. The present study identified that choice between LC or MC 
lipids was highly drug specific, with advantages of LC systems (i.e. LCM and LCM+S) 
for celecoxib and cinnarizine and of the single component MCM system for JNJ-2A. 
The in vivo exposure of cinnarizine has previously been reported to benefit from 
LBDDS containing LCT (as either a lipid solution or nanoemulsion) [25,37], whereas, 










digested LCT (i.e.blends of mono-/di-glycerides) was not reported before. While further 
studies on a broader set of drugs would be required for clear correlations to be 
established between drug properties and lipid chain length, the observations here 
indicate that preformulation screenings should be performed with both LC and MC 
based excipients.  
In vitro dilution and dispersion testing in FaSSIF can be employed for early 
stage physiological characterization of LBDDS [5] and was thus performed in this study 
to assess the precipitation risk and kinetic drug concentration profile for the range of 
LBDDS. The three component LBDDS displayed improved dispersibility in FaSSIF, a 
relatively high drug concentration in the aqueous phase, but also evidence of drug 
precipitation (celecoxib and cinnarizine). Interestingly these systems displayed lower in 
vivo absorption which may reflect the higher precipitation potential for these systems. In 
contrast, despite limited dispersibility for the single or two component LBDDS (LCM, 
LCM+S, MCM, MCM+S) in vivo bioavailability tended to be higher and this was 
matched by a general trend towards longer time to precipitate (e.g. LCM, LCM+S, 
MCM for celecoxib and cinnarizine). These observations therefore provide stronger 
support to the claim that designing LBDDS to maximise in vitro dispersibility provides 
limited insights on to the likely in vivo effects. In contrast, factors such as precipitation 
and solubilisation capacity are more likely to provide predictive insights [15]. 
Furthermore, Larsen et al. have shown for danazol that higher bioavailability of Labrafil 
M2125CS formulations with low drug loadings were corelated to higher drug 
concentration in the aqueous environment of lipolysis media and limited drug 
precipitation [40,41].   
By plotting the calculated AUC in vitro versus AUC in vivo, no strong 










to 0.017 for celecoxib and 0.006 for JNJ-2A. Nevertheless, the good performance of 
LCM+S for celecoxib, cinnarizine and JNJ-2A and the poorer performance of MCM 
and MCM+S for celecoxib and cinnarizine may have been anticipated from low drug 
solubilization in biorelevant media. The promotion of such simple in vitro screening 
tests for formulation ranking is encouraged in early development in lieu of more 
complex tests (e.g. dynamic lipolysis) for an easily accessible and HTS characterization 
tool [15]. The dilution and dispersion testing was beneficial to identify higher risk 
formulation strategies in early stages of development and was proposed as a first tier 
testing in the revised LFCS reports [42]. Yet, the power to predict in vivo scenarios is 
limited and this test needs adjustments in order to be considered as a platform for in 
vitro LBDDS screening in industrial development. For cinnarizine, a weak correlation 
(R
2
 = 0.39) was previously reported between the in vivo AUC after administration of 
four LBDDS to dogs and in vitro AUC observed in the % cinnarizine in the aqueous 
phase of a pH-stat lipolysis test after 60 min digestion [3]. 
Another in vitro test investigated in this study was the drug solubilization in 
different biorelevant media containing dispersed lipid excipients or their respective 
digestion products, which may give early indication on the solubilization capacity of the 
system formed upon dispersion and digestion of LBDDS in the GIT. Gautschi et al. 
previously suggested that the assembled medium representative of post-digestive 
conditions for the MC lipid excipient used in this study (i.e. Capmul MCM) was indeed 
reflecting the solubilization capacity observed in medium containing enzymatically 
digested lipid excipient [21]. In the present study, the data set was enriched with the 
addition of LCM dispersed and digested media. It was observed that addition of 
digestion products of LCM could reach the same drug solubilization capacity as FeSSIF 










effect presented by the three tested drugs. In almost all cases (exception being JNJ-2A 
in MC media) the solubilization capacity of assembled post-digestive was higher than 
the solubility in the dispersed media indicating that the digestion step was essential for 
the solubilization enhancement in the simulated GIT environment for the three 
investigated drugs. The results for celecoxib (weak acid) and JNJ-2A (neutral) were in 
contradiction to conclusions by Alskär et al. who presented drug solubility for 6 drugs 
(3 weak acids and 3 neutral) to be higher in dispersion media when compared to post-
digestive media [43]. Nevertheless, the experimental design of the approach by Alskär 
and co-workers was different compared to the one used in this study as the LBDDS 
were type IIIA, IIIB and IV (i.e. containing 35% surfactant), the LBDDS were lipolysed 
and the pH adjusted to 6.5 during the solubility studies, which was not done in the 
present work. 
In the current study, limited information can be extracted for cinnarizine and 
JNJ-2A in the MC media as a result of drug tendency to form agglomerates with 
lipolytic products; however, cinnarizine was shown to have a higher solubility in the 
aqueous phase of LCT digests relative to MCT in a study performed by Kaukonen and 
co-workers [44] which was in line with the present results. The test had limited power 
in predicting the in vivo differences observed for LCM and MCM systems, as it showed 
a higher solubility for MC media for celecoxib and for LC media in case of JNJ-2A 
while the in vivo performance was reversed.  However, the test had indicative power for 
cinnarizine, and it may serve as a starting point to determine drug solubilization in 












This study adopted a simplified approach to LBDDS formulation design, and 
demonstrated the merits of using mono-/di-glycerides as single component excipients in 
LBDDS, offering a balance in terms of streamlining formulation screening and 
improving oral bioavailability. MCM and LCM displayed a higher solvent capacity for 
the three PWSD, relative to triglyceride equivalents. Despite relatively poor 
dispersibility in vitro, the observations from the in vivo pharmacokinetic dosing of a 
range of increasingly complex LBDDS to rats, confirmed the merits of one 
(LCM/MCM) or two component (LCM/MCM + surfactant) systems, relative to three 
component systems (LCM/MCM + surfactant + LCT/MCT). In terms of the choice of 
LC versus MC based systems, this study indicated that LC systems displayed higher 
drug solubilization in simulated biorelevant media and a lower propensity for drug 
precipitation relative to MC systems. However, in terms of in vivo observations, the 
choice of excipient type appears to be drug specific, with LC systems favorable for 
celecoxib and cinnarizine whereas MC based systems were preferred for JNJ-2A. While 
two in vitro methods were evaluated for assessing formulation dispersion, digestion and 
solubilization under biorelevant conditions, in general the in vitro results were poorly 
predictive of in vivo effects observed across the range of formulations explored. From 
an industrial drug development perspective, it would appear that further advances on 
high throughput and bio-predictive in vitro screening approaches are needed to guide 
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Table 1. Quantity of drug (mg) loaded per mL of lipid-based drug delivery systems. 
This dose loading corresponds to 85% of the saturated solubility of the drug reported 
previously in Ilie et al. [45]. (LCM = long chain mono/di- glycerides blends (Maisine 
CC, Ma), MCM = medium chain mono-/di- glycerides blends (Capmul MCM, Ca), 
LCT = long chain triglycerides (Sesame oil, SO), MCT = medium chain triglycerides 
(Labrafac Lipophile, LL), S = surfactant (Labrasol ALF, L). 
 
LBDDS Composition (w:w) 
Quantity added (mg per ml of LBDDS) 
Celecoxib Cinnarizine JNJ-2A 
LCM Ma  15.8 47.0 46.8 
MCM Ca 57.4 41.3 296.1 
LCM+S Ma + L (4:1) 62.2 37.3 193.0 
MCM+S Ca + L (4:1) 80.9* 39.4 392.2 
LCM+LCT+S Ma + SO + L (2:2:1) 71.0 31.7 n.a.* 
MCM+MCT+S Ca + LL + L (2:2:1) 102.7 42.1 309.9 
LCM+MCT+S Ma + LL + L (2:2:1) 82.5 39.7 n.a.* 
MCM+LCT+S Ca + SO + L (2:2:1) 83.3 41.2 n.a.* 
n.a.* = not prepared based on preformulation studies which showed lack of excipient 
compatibility after JNJ-2A loading [45] 











Table 2. Dose (mg/kg) administered orally to fasted Sprague-Dawley rats in a 
pharmacokinetic study. 
LBDDS Composition (w:w) 
Dose (mg/kg) 
Celecoxib Cinnarizine JNJ-2A 
LCM Ma  7.9 23.5 23.4 
MCM Ca 28.7 20.7 148.1 
LCM+S Ma + L (4:1) 31.1 18.7 96.5 
MCM+S Ca + L (4:1) 40.5 19.7 196.1 
LCM+LCT+S Ma + SO + L (2:2:1) 35.5 15.9 n.a.* 
MCM+MCT+S Ca + LL + L (2:2:1) 51.4 21.1 155.0 
LCM+MCT+S Ma + LL + L (2:2:1) 41.3 19.9 n.a.* 
MCM+LCT+S Ca + SO + L (2:2:1) 41.7 20.6 n.a.* 
n.a.* = not administered based on preformulation studies which showed lack of excipient 











Table 3. Pharmacokinetic parameters Cmax, AUC0-24h (mean ± SD) and tmax (median, 
[min, max]) following single oral administration of lipid-based drug delivery systems 
containing celecoxib, cinnarizine or JNJ-2A at 85% saturation degree. 
 
LBDDS 
























LCM 429 ± 78
a
 3564 ± 984 
1.5 [1.0; 
4.0] 
34 ± 12 285 ± 76
d






MCM 237 ± 52
a





















 255 ± 59 
2.0 [ 2.0; 
4.0] 
47.9 ± 3.1 574 ± 50 
7.0 [4.0; 
7.0] 
MCM + S 270 ± 63
a











LCT + S 
246 ± 47
a
 2642 ± 748 
2.0 [1.0; 
4.0] 
31 ± 18 193 ± 44 2.0 [1.0; 4.0] Not available 
MCM + 
MCT + S 
236 ± 32
a
 2576 ± 304 
4.0 [4.0; 
4.0] 





MCT + S 
305 ± 48
a





196 ± 56 1.0 [1.0; 2.0] Not available 
MCM + 
LCT + S 
221 ± 21
a
 2658 ± 257 
4.0 [4.0; 
6.0] 
26 ± 12 196 ± 63
 
1.0 [1.0, 2.0] Not available 
a
LCM statistically different from all other lipid systems, except LCM+S 
b
 LCM+S statistically different from MCM 
c
 LCM+S statistically different from MCM 
d 
LCM statistically different from MCM+S 
e 












Figure 1. Solubility (mean + SD, mg/mL) in blends of mono- and di-glycerides (LCM-
Maisine CC and MCM-Capmul MCM) and triglycerides (LCT-sesame oil and MCT-
Labrafac Lipophile). Black bars depict data for celecoxib, dark grey bars for cinnarizine 












Figure 2. Apparent solubility (mean + SD, µg/ml) of celecoxib, cinnarizine and JNJ-2A 







Figure 3. Percentage of drug solubilized in aqueous dispersed phase upon dilution and 
dispersion of lipid-based drug delivery systems containing celecoxib, cinnarizine and 
JNJ-2A at 85% saturation degree (mean + SD, n=3): continuous lines – LCM systems: 
LCM (full circles), LCM+S (full squares), LCM+LCT+S (full triangles), 
LCM+MCT+S (full diamonds); interrupted lines – MCM systems: MCM (empty 












Figure 4. Plasma concentration-time profiles (mean + SD), n=4 for celecoxib and 
cinnarizine after dosing eight LBDDS and n=6 for JNJ-2A  after oral dosing of five 
LBDDS. Continuous lines – LCM systems: LCM (full circles), LCM+S (full squares), 
LCM+LCT+S (full triangles), LCM+MCT+S (full diamonds); interrupted lines – 
MCM-based systems: MCM (empty circles), MCM+S (empty squares), MCM+LCT+S 
(empty triangles), MCM+MCT+S (empty diamonds). 
 
 
Figure 5. Area under the concentration-time plasma profiles obtained after oral 
administration of LBDDS containing celecoxib, cinnarizine and JNJ-2A. Full colour 
bars represent LCM lipid systems and dotted bars represent MCM lipid systems. Data 












Figure 6.  In vitro - in vivo relations of drug absorption after administration of LBDDS 
to male fasted rats (AUC0-24h) and drug solubilization after dispersion of LBDDS as 
drug concentration in aqueous phase (total drug in free form in solution plus solubilized 
in dispersed phase); A) celecoxib, B) cinnarizine, C) JNJ-2A. 
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